The Marriage of Small Molecules and Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Marriage of Small Molecules and Biologics
Approaches in using small-molecule and peptide synthesis offer promise in widening the scope of drug candidates.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 56-60

Other approaches

Improving peptide synthesis also is an area of ongoing research. Researchers from Vanderbilt University recently reported their efforts in overcoming a limitation in peptide synthesis, the incorporation of non-natural amino acids into the peptide chain. The researchers noted that creation of amide bonds typically use methods that principally are based on dehydrative approaches or oxidative and radical-based methods. Generally, carbon and nitrogen bear electrophilic and nucleophilic character, respectively, during the carbon–nitrogen bond-forming step. In their work, the researchers showed the activation of amines and nitroalkanes with an electrophilic iodine source to directly make amide products. The suggested mechanism showed that the polarities of the two reactants were reversed during carbon–nitrogen bond formation relative to traditional approaches. Looking forward, the researchers noted that using nitroalkanes as acyl anion equivalents provides a conceptually innovative approach to amide and peptide synthesis, and one that may further engender more efficient peptide synthesis that relies on enantioselective methods (7).

"Scientists from many disciplines have sought improved methods to streamline the synthesis of peptides through purely chemical means in order to increase the diversity of the chemical tools available for the design of improved therapeutics," said Jeff Johnston, professor of chemistry at Vanderbilt University, in a June 23, 2010, Vanderbilt University press release. "Our discovery of a conceptually new approach to peptide synthesis brings this capability much closer to reality."

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,
.

References

1. T. Sawyer, Chem. Biol. Drug. Des. 73 (1), 3–6 (2009).

2. W. Wolfson, Chem. & Biol. 16 (9), 910–911 (2009).

3. J.B. Binder and R. Raines, Curr. Opin. Chem. Biol. 12 (6), 767–773 (2008).

4. H.E. Blackwell and R. Grubbs, Angew. Chem. Int. Ed. 37, 3281–3284 (1998).

5. G.H. Bird et al., Proc. Natl. Acad. Sci., DOI/10.1073pnas.1002713107 (June 18, 2010).

6. Q. Lin et al., Biorg. Med. Chem. Lett. 21 (5) 1472–1475 (2011).

7. B. Shen, D. Makely, and J.N. Johnston., Nature 465 (7301), 1027–1032 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here